SCHEMBL15465950

SCHEMBL15465950

FC(F)(F)c1cccc2scnc12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
HSD17B10 Q99714 1/20 0.41
PARP1 P09874 1/20 0.40
TDP1 Q9NUW8 1/20 0.36
MPL P40238 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
NCF1 P14598 1/20 0.34
P2RX7 Q99572 4/20 0.34
AXL P30530 1/20 0.33
HSD11B1 P28845 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
PKLR P30613 2/20 0.33
TRPV1 Q8NER1 1/20 0.33
GRM2 Q14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL761991 0.85 ALDH1A1 (0.41) ALDH1A1HSD17B10TDP1PKLRTRPV1
SCHEMBL12637455 0.84 CYP3A4 (0.39) ALDH1A1HSD17B10TDP1MPLHSD11B1
SCHEMBL5780908 0.74 WDR5 (0.33) ALDH1A1HSD17B10MPL
SCHEMBL744132 0.74 SMN1; SMN2 (0.46) ALDH1A1HSD17B10PARP1TDP1L3MBTL1
SCHEMBL29967087 0.74 ALDH1A1 (0.46) ALDH1A1HSD17B10PARP1GAAMAPT
SCHEMBL9720829 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10
SCHEMBL288904 0.74 ALDH1A1 (0.46) ALDH1A1HSD17B10PARP1GAAMAPT
SCHEMBL22430396 0.73 ALDH1A1 (0.32) ALDH1A1HSD17B10PKLRTRPV1
SCHEMBL1880384 0.73 NAMPT (0.46) ALDH1A1HSD17B10MEN1KMT2A
Benzene SCHEMBL9304849 0.72 ALDH1A1 (0.43) ALDH1A1HSD17B10TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-12577240-B2 Antiviral heteroaryl ketone derivatives PFIZER INC. (US) 2026-03-17 US disclosed
US-20250171438-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2025-05-29 US disclosed
CN-117858865-A CBL-B modulators and uses thereof 林伯士克莱奥公司 2024-04-09 CN disclosed
US-20230339930-A1 Antiviral Heteroaryl Ketone Derivatives PFIZER INC. (US) 2023-10-26 US disclosed
US-20230339930-A1 Antiviral Heteroaryl Ketone Derivatives PFIZER INC. (US) 2023-10-26 US disclosed
US-20230339930-A1 Antiviral Heteroaryl Ketone Derivatives PFIZER INC. (US) 2023-10-26 US disclosed
EP-3183250-B1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL CLAP CO LTD (KR) 2023-10-04 EP disclosed
WO-2023164237-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2023-08-31 WO disclosed
WO-2023164237-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2023-08-31 WO disclosed
CN-107074857-A Method for preparing crystallization organic semiconducting materials 巴斯夫欧洲公司 2017-08-18 CN disclosed
US-20170237005-A1 PROCESS FOR PREPARING A CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL BASF SE (DE) 2017-08-17 US disclosed
CN-107004768-A Organic semiconductor composition containing a liquid medium 巴斯夫欧洲公司 2017-08-01 CN disclosed
EP-3183250-A1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL BASF SE (DE) 2017-06-28 EP disclosed
EP-3183757-A1 ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM BASF SE (DE) 2017-06-28 EP disclosed
US-9293711-B2 Organic semiconductor formulations POLYERA CORPORATION (US) 2016-03-22 US disclosed
WO-2016027218-A1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL BASF SE (DE) 2016-02-25 WO disclosed
WO-2016027217-A1 ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM BASF SE (DE) 2016-02-25 WO disclosed
CN-105209444-A Benzo-fused heterocyclic derivatives useful as agonists of GPR120 JANSSEN PHARMACEUTICA NV 2015-12-30 CN disclosed
US-20140042369-A1 Organic Semiconductor Formulations USINVEST LLC 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577240-B2 Antiviral heteroaryl ketone derivatives ACE2, SARS1, ACE ALDH1A1 1752/4885HSD17B10 525/4885PARP1 371/4885
US-20230339930-A1 Antiviral Heteroaryl Ketone Derivatives ACE2, ZC3HAV1, SARS1 ALDH1A1 1519/4885HSD17B10 562/4885PARP1 61/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR ALDH1A1 4757/4885HSD17B10 4363/4885PARP1 4793/4885
US-20250171438-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 ALDH1A1 865/4885HSD17B10 1477/4885PARP1 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.